Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Ischemic Heart Disease

In brief

ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.

Key facts

Study ID

NCT07192211

Run by

Rohto Pharmaceutical Co., Ltd.

People needed

50

Starts

2026-04-28

Expected to finish

2029-03-31

Last updated by the study team

2026-06-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients clinically diagnosed with chronic heart failure due to ischemic heart disease who undergo CABG
• Patients with an LVEF of less than 40% as determined by the cardiac ultrasound at the screening examination.
• Others

You may not qualify if…

• Patients who have a combination of cardiovascular disease such as severe organic valvular disease.
• Patients who have developed acute coronary syndrome within 3 months prior to obtaining consent.
• Others

Where it is running

• The University of Osaka Hospital — Osaka, Suita, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.